Recce Ltd has released a press release.
R327 Phase I Study - Australias CMAX Clinical Facility
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Positive & Concentration-Dependent Efficacy Against COVID-19
- Recce Pharmaceuticals Receives Innovation Connections Grant
- Recce Pharmaceuticals Appoints James Graham as CEO
- Positive Oral Data on New RECCE 435 Against H. pylori
- US Researchers to Test RECCE in Expanded SARS-CoV-2 Program
Later from Recce Pharmaceuticals
- Recce Completes Capital Raising of $27.95m
- Murdoch Childrens Research Institute, R435 Against H.Pylori
- HREC Approval to Start Phase I/II Burns Wound Study
- Encouraging Results Against SARS-CoV-2 Virus
- Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals